Tivic Health Systems Shifts Focus to Biopharmaceuticals

Tivic Health Systems ( (TIVC) ) has shared an update.

On August 14, 2025, Tivic Health Systems announced its financial results for the quarter ending June 30, 2025, revealing a strategic shift towards biopharmaceuticals and plans to exit its consumer healthtech business by year-end. The company reported decreased revenue due to lower sales of its ClearUP product, but highlighted advancements in its TLR5 agonist program and preparations for FDA applications. Key developments included securing interest in military applications for Entolimod, extending its license for treating neutropenia, and raising funds through equity agreements. Despite a net loss, Tivic is optimistic about its transformation strategy and future growth.

Spark’s Take on TIVC Stock

According to Spark, TipRanks’ AI Analyst, TIVC is a Neutral.

The overall stock score of 43 reflects Tivic Health Systems’ current financial difficulties, including declining revenues and negative profitability. However, recent strategic initiatives and corporate events provide some optimism for future growth. The stock’s technical indicators and valuation remain weak, necessitating significant improvements in financial performance and market sentiment to enhance stock attractiveness.

To see Spark’s full report on TIVC stock, click here.

More about Tivic Health Systems

Tivic Health Systems, Inc. is a diversified immunotherapeutics company that utilizes both biopharmaceutical and bioelectronic systems to address unmet medical needs. The company is focused on developing treatments that target the immune system, with a lead drug candidate, Entolimod, for acute radiation syndrome, and a bioelectronic program aimed at non-invasive medical devices.

Average Trading Volume: 30,960

Technical Sentiment Signal: Sell

Current Market Cap: $3.76M

For a thorough assessment of TIVC stock, go to TipRanks’ Stock Analysis page.